Impact of comorbidity in DBLCL: direct and indirect effects on survival through unplanned chemotherapy dose reduction

J Intern Med. 2019 Apr;285(4):472-474. doi: 10.1111/joim.12879. Epub 2019 Feb 15.

Authors

S Lamy¹, G Laurent^{1

2}, B Lepage^{1

3}, P Grosclaude^{1

4}, C Delpierre¹

Affiliations

¹ Inserm, UMR1027, Université Toulouse III, Toulouse, France.
² Département d'hématologie, Institut Universitaire du Cancer de Toulouse- Oncopole (IUCT-O), Toulouse, France.
³ Service d'Epidémiologie, CHU de Toulouse, Toulouse, France.
⁴ Registre du Cancer du Tarn, Albi, France.

PMID: 30681214
DOI: 10.1111/joim.12879

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Comorbidity
Humans
Lymphoma, Large B-Cell, Diffuse*
Sweden